Joel Greenblatt's PTCT Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 18,056 shares of PTC Therapeutics, Inc. (PTCT) worth $1.11 M, representing 0.00% of the portfolio. First purchased in 2017-Q3, this long-term strategic position has been held for 33 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in PTCT, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 30,829 shares. Largest reduction occurred in Q3 2025, reducing 17,573 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2017 | +19,796 | New Buy | 19,796 | $20.00 |
| Q4 2017 | -19,796 | Sold Out | 19,796 | $0.00 |
| Q2 2018 | +12,151 | New Buy | 12,151 | $33.74 |
| Q3 2018 | +689 | Add 5.67% | 12,840 | $46.96 |
| Q4 2018 | -1,761 | Reduce 13.71% | 11,079 | $34.30 |
| Q1 2019 | -11,079 | Sold Out | 11,079 | $0.00 |
| Q2 2019 | +5,133 | New Buy | 5,133 | $45.00 |
| Q3 2019 | -5,133 | Sold Out | 5,133 | $0.00 |
| Q4 2019 | +5,133 | New Buy | 5,133 | $48.12 |
| Q1 2020 | +37 | Add 0.72% | 5,170 | $44.68 |
| Q2 2020 | -51 | Reduce 0.99% | 5,119 | $50.79 |
| Q4 2020 | -333 | Reduce 6.51% | 4,786 | $61.01 |
| Q1 2021 | -1 | Reduce 0.02% | 4,785 | $47.44 |
| Q3 2021 | -4,785 | Sold Out | 4,785 | $0.00 |
| Q2 2022 | +6,599 | New Buy | 6,599 | $40.01 |
| Q3 2022 | +456 | Add 6.91% | 7,055 | $50.18 |
| Q4 2022 | -250 | Reduce 3.54% | 6,805 | $38.17 |
| Q1 2023 | +5,512 | Add 81.00% | 12,317 | $48.44 |
| Q2 2023 | -5,536 | Reduce 44.95% | 6,781 | $40.67 |
| Q3 2023 | -6,781 | Sold Out | 6,781 | $0.00 |
| Q1 2024 | +7,527 | New Buy | 7,527 | $29.09 |
| Q2 2024 | -7,527 | Sold Out | 7,527 | $0.00 |
| Q1 2025 | +4,800 | New Buy | 4,800 | $50.96 |
| Q2 2025 | +30,829 | Add 642.27% | 35,629 | $48.84 |
| Q3 2025 | -17,573 | Reduce 49.32% | 18,056 | $61.37 |
Joel Greenblatt's PTC Therapeutics Investment FAQs
Joel Greenblatt first purchased PTC Therapeutics, Inc. (PTCT) in Q3 2017, acquiring 19,796 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held PTC Therapeutics, Inc. (PTCT) for 33 quarters since Q3 2017. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q2 2025, adding 35,629 shares worth $1.74 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 18,056 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $1.11 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in PTC Therapeutics, Inc. (PTCT) was 35,629 shares, as reported at the end of Q2 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.